Teva Pharmaceutical Industries annual free cash flow
2007
2008
2009
2010
2011
2012
2013
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Free Cash Flow (FCF) History (TEVA)
Teva Pharmaceutical Industries reported $1.15B in free cash flow for fiscal 2025, an increase of 53.27% from the previous fiscal year, with a free cash flow margin of 6.65%.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.15B | $399.0M | +53.27% | +6.65% |
| 2024 | 2024-12-31 | $749.0M | −$93.0M | −11.05% | +4.53% |
| 2023 | 2023-12-31 | $842.0M | −$200.0M | −19.19% | +5.31% |
| 2022 | 2022-12-31 | $1.04B | $806.0M | +341.53% | +6.98% |
| 2021 | 2021-12-31 | $236.0M | −$402.0M | −63.01% | +1.49% |
| 2020 | 2020-12-31 | $638.0M | $415.0M | +186.10% | +3.83% |
| 2019 | 2019-12-31 | $223.0M | −$1.57B | −87.58% | +1.32% |
| 2018 | 2018-12-31 | $1.79B | −$411.0M | −18.63% | +9.82% |
| 2013 | 2013-12-31 | $2.21B | −$1.26B | −36.39% | +10.86% |
| 2012 | 2012-12-31 | $3.47B | $387.0M | +12.56% | +17.07% |
| 2011 | 2011-12-31 | $3.08B | −$345.0M | −10.07% | +16.83% |
| 2010 | 2010-12-31 | $3.43B | $772.0M | +29.09% | +21.25% |
| 2009 | 2009-12-31 | $2.65B | $104.0M | +4.08% | +16.46% |
| 2008 | 2008-12-31 | $2.55B | $1.28B | +100.63% | +23.00% |
| 2007 | 2007-12-31 | $1.27B | — | — | +13.51% |
Teva Pharmaceutical Industries quarterly free cash flow
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $307.0M | $176.0M | +134.35% | +7.41% |
| Q1 2026 | 2026-03-31 | −$208.0M | $24.0M | — | −5.22% |
| Q4 2025 | 2025-12-31 | $1.02B | $570.0M | +127.80% | +21.57% |
| Q3 2025 | 2025-09-30 | $233.0M | −$312.0M | −57.25% | +5.20% |
| Q2 2025 | 2025-06-30 | $131.0M | $125.0M | +2083.33% | +3.14% |
| Q1 2025 | 2025-03-31 | −$232.0M | $16.0M | — | −5.96% |
| Q4 2024 | 2024-12-31 | $446.0M | −$619.0M | −58.12% | +10.55% |
| Q3 2024 | 2024-09-30 | $545.0M | $689.0M | — | +12.58% |
| Q2 2024 | 2024-06-30 | $6.0M | −$199.0M | −97.07% | +0.14% |
| Q1 2024 | 2024-03-31 | −$248.0M | $36.0M | — | −6.49% |
| Q4 2023 | 2023-12-31 | $1.06B | $107.0M | +11.17% | +23.89% |
| Q3 2023 | 2023-09-30 | −$144.0M | −$438.0M | — | −3.74% |
| Q2 2023 | 2023-06-30 | $205.0M | $209.0M | — | +5.29% |
| Q1 2023 | 2023-03-31 | −$284.0M | −$78.0M | — | −7.76% |
| Q4 2022 | 2022-12-31 | $958.0M | $655.0M | +216.17% | +24.67% |
| Q3 2022 | 2022-09-30 | $294.0M | −$89.0M | −23.24% | +8.18% |
| Q2 2022 | 2022-06-30 | −$4.0M | −$109.0M | — | −0.11% |
| Q1 2022 | 2022-03-31 | −$206.0M | $349.0M | — | −5.63% |
| Q4 2021 | 2021-12-31 | $303.0M | $148.0M | +95.48% | +7.39% |
| Q3 2021 | 2021-09-30 | $383.0M | $219.0M | +133.54% | +9.85% |
| Q2 2021 | 2021-06-30 | $105.0M | −$37.0M | −26.06% | +2.69% |
| Q1 2021 | 2021-03-31 | −$555.0M | −$732.0M | — | −13.94% |
| Q4 2020 | 2020-12-31 | $155.0M | −$264.0M | −63.01% | +3.48% |
| Q3 2020 | 2020-09-30 | $164.0M | $8.0M | +5.13% | +4.12% |
| Q2 2020 | 2020-06-30 | $142.0M | $481.0M | — | +3.67% |
| Q1 2020 | 2020-03-31 | $177.0M | $190.0M | — | +4.06% |
| Q4 2019 | 2019-12-31 | $419.0M | $265.0M | +172.08% | +9.38% |
| Q3 2019 | 2019-09-30 | $156.0M | −$126.0M | −44.68% | +3.81% |
| Q2 2019 | 2019-06-30 | −$339.0M | −$365.0M | — | −8.12% |
| Q1 2019 | 2019-03-31 | −$13.0M | −$1.35B | — | −0.31% |
| Q4 2018 | 2018-12-31 | $154.0M | −$429.0M | −73.58% | +3.87% |
| Q3 2018 · Sep 30 | 2018-09-30 | $282.0M | $40.0M | +16.53% | +6.23% |
| Q2 2018 · Jun 30 | 2018-06-30 | $26.0M | $92.0M | — | +0.55% |
| Q1 2018 · Mar 31 | 2018-03-31 | $1.33B | $93.0M | +7.50% | +26.32% |
| Q3 2018 · Sep 30 | 2017-09-30 | $583.0M | −$205.0M | −26.02% | +10.38% |
| Q2 2018 · Jun 30 | 2017-06-30 | $242.0M | −$962.0M | −79.90% | +4.23% |
| Q1 2018 · Mar 31 | 2017-03-31 | −$66.0M | −$989.0M | — | −1.17% |
| Q3 2017 | 2016-09-30 | $1.24B | −$71.0M | −5.42% | +22.29% |
| Q2 2017 | 2016-06-30 | $788.0M | −$381.0M | −32.59% | +15.64% |
| Q1 2017 | 2016-03-31 | $1.20B | −$8.0M | −0.66% | +25.03% |
| Q3 2016 | 2015-09-30 | $923.0M | $62.0M | +7.20% | +19.14% |
| Q2 2016 | 2015-06-30 | $1.31B | $638.0M | +94.80% | +26.40% |
| Q1 2016 | 2015-03-31 | $1.17B | $953.0M | +441.20% | +23.46% |
| Q3 2014 | 2014-09-30 | $1.21B | $562.0M | +86.46% | +23.96% |
| Q2 2014 | 2014-06-30 | $861.0M | $23.0M | +2.74% | +17.07% |
| Q1 2014 | 2014-03-31 | $673.0M | −$577.0M | −46.16% | +13.46% |
| Q3 2013 | 2013-09-30 | $216.0M | −$583.0M | −72.97% | +4.27% |
| Q2 2013 | 2013-06-30 | $650.0M | −$287.0M | −30.63% | +13.20% |
| Q1 2013 · Mar 31 | 2013-03-31 | $838.0M | $356.0M | +73.86% | +17.10% |
| Q4 2012 | 2012-12-31 | $1.25B | $139.0M | +12.51% | +23.33% |
| Q3 2012 | 2012-09-30 | $799.0M | $593.0M | +287.86% | +16.07% |
| Q2 2012 | 2012-06-30 | $937.0M | −$161.0M | −14.66% | +18.76% |
| Q1 2012 | 2012-03-31 | $482.0M | −$184.0M | −27.63% | +9.65% |
| Q4 2011 | 2011-12-31 | $1.11B | $243.0M | +28.00% | +19.57% |
| Q3 2011 | 2011-09-30 | $206.0M | −$813.0M | −79.78% | +4.74% |
| Q2 2011 | 2011-06-30 | $1.10B | $280.0M | +34.23% | +26.07% |
| Q1 2011 | 2011-03-31 | $666.0M | −$55.0M | −7.63% | +16.32% |
| Q4 2010 | 2010-12-31 | $868.0M | $123.0M | +16.51% | +19.65% |
| Q3 2010 | 2010-09-30 | $1.02B | $190.0M | +22.92% | +23.98% |
| Q2 2010 | 2010-06-30 | $818.0M | $311.0M | +61.34% | +21.53% |
| Q1 2010 | 2010-03-31 | $721.0M | $148.0M | +25.83% | +19.74% |
| Q4 2009 | 2009-12-31 | $745.0M | −$43.0M | −5.46% | +12.37% |
| Q3 2009 | 2009-09-30 | $829.0M | $297.0M | +55.83% | +23.35% |
| Q2 2009 | 2009-06-30 | $507.0M | −$119.0M | −19.01% | +14.91% |
| Q1 2009 | 2009-03-31 | $573.0M | −$31.0M | −5.13% | +18.21% |
| Q4 2008 | 2008-12-31 | $788.0M | — | — | +27.67% |
| Q3 2008 | 2008-09-30 | $532.0M | — | — | +18.72% |
| Q2 2008 | 2008-06-30 | $626.0M | — | — | +22.17% |
| Q1 2008 | 2008-03-31 | $604.0M | — | — | +23.48% |
Teva Pharmaceutical Industries free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $638.0M to $1.15B, a compound annual growth rate of 12.47%. Teva Pharmaceutical Industries's latest reported quarter, Q2 2026, generated $307.0M in free cash flow, an increase of 134.35% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Teva Pharmaceutical Industries filings at SEC.gov ↗